Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia

M Waibel; S J Vervoort; I Y Kong; S Heinzel; K M Ramsbottom; B P Martin; E D Hawkins; R W Johnstone

doi:10.1038/leu.2017.282

Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia

Leukemia. 2018 Jan;32(1):237-241. doi: 10.1038/leu.2017.282. Epub 2017 Sep 15.

Authors

M Waibel^{1

2

3}, S J Vervoort^{1

2

3}, I Y Kong^{4

5}, S Heinzel^{4

5}, K M Ramsbottom², B P Martin¹, E D Hawkins^{4

5}, R W Johnstone^{1

2

3}

Affiliations

¹ Cancer Therapeutics, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
² Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
³ Sir Peter MacCallum Department of Oncology, The University of Melbourne, Australia.
⁴ The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia and.
⁵ Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia.

PMID: 28914259
DOI: 10.1038/leu.2017.282

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Epigenesis, Genetic / drug effects*
Epigenesis, Genetic / genetics
Epigenomics / methods
Histone Deacetylase Inhibitors / pharmacology
Humans
Leukemia, T-Cell / drug therapy*
Leukemia, T-Cell / genetics
Panobinostat / pharmacology*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics
Receptor, Notch1 / genetics*
T-Lymphocytes / drug effects*
Transcription, Genetic / drug effects*
Transcription, Genetic / genetics

Substances

Histone Deacetylase Inhibitors
Receptor, Notch1
Panobinostat